Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation

This open-label, phase 1–2, single-center study examined the use of intravenous immune globulin and rituximab to reduce anti-HLA antibodies and improve transplantation rates in 20 highly sensitized patients. Sixteen patients (80%) subsequently received a transplant, and the 1-year survival rates for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2008-07, Vol.359 (3), p.242-251
Hauptverfasser:	Vo, Ashley A, Lukovsky, Marina, Toyoda, Mieko, Wang, Jennifer, Reinsmoen, Nancy L, Lai, Chih-Hung, Peng, Alice, Villicana, Rafael, Jordan, Stanley C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies - blood Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antigens, CD19 - blood Antigens, CD20 - immunology Biological and medical sciences Creatinine - blood Desensitization, Immunologic - methods Drug Therapy, Combination Female General aspects Graft Rejection - epidemiology HLA Antigens - immunology Humans Immunoglobulins, Intravenous - adverse effects Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Immunosuppression - methods Kidney Transplantation - immunology Male Medical sciences Middle Aged Pharmaceutical industry Rituximab Studies Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Survival Rate Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!